#### EXHIBIT 65

**Produced in Native Format** 



### Modified-Release Opioid Risk Management Program: Safety Overview

Linda Kitlinski Senior Director, Clinical Development & Education Endo Pharmaceuticals

# What Is a Risk Management Program?

- A Risk Management Program (RMP) is a program of activities designed to
  - Minimize the risks associated with medications
  - Maximize the benefits of medications
  - Ensure patient safety
- Manage risk by developing proactive risk management strategies
- Minimize the need for reactive responses



## Modified-Release Opioid RMP: Content Overview

- Objectives
  - Estimate and evaluate risk
  - Manage known risks associated with a drug
  - Optimize risk/benefit ratio
    - Balance benefits gained from the medication with potential risks
  - Promote safe use of the medication
  - Protect public health



# Modified-Release Opioid RMP: Key Elements

- Risk of accidental exposure
  - Especially in modified-release products with large amounts of opioid
- Risk of improper patient selection
  - Who are the appropriate patients?
- Risk for abuse and misuse
  - How can we reduce risk for patients and the community?



## Modified-Release Opioid RMP: Content Overview

- Endo's RMP
  - Minimize misuse/abuse and diversion of opioids via the components of RM
    - Risk Assessment
    - Risk Management/Intervention
    - Risk Communication/Education



### Risk Assessment

- Challenges of risk assessment:
  - How prevalent is abuse/diversion?
    - Absence of good data
    - Spectrum of populations
      - Acute pain pts? Chronic pain pts? Addicts?
      - Background rates?
  - How to assess potential for abuse/misuse?
    - Lack of well-validated tools, yet
    - NEED to assess relative risk of aberrant behaviors



### S Case 1:17-mol-02804=DAP Dote #: 2181-71 Filed: 08/12/19 9 of 31. PageID #: 325868:

### Screener and Opioid Assessment for Patients with Pain

- 1st prospectively-validated opioid assessment screener
  - Being developed under NIDA/NIH grant to Inflexxion
- Practical tool to help predict relative potential to <u>misuse</u> opioid medications
  - Addiction, diversion, recreational use
- For use in pts being considered for long-term opioid tx
  - Purpose is NOT to deny pts access to pain medication
  - Purpose is NOT to "screen in" or "screen out"
- Purpose Is to assist clinician in deciding:
  - Level of monitoring a given patient may require
  - If multidisciplinary or pain consult would be useful
  - Help document decisions




### S.O.A.P.P

### Screener and Opioid Assessment for Patients with Pain

- Brief, self-report screener
  - 5-10 minutes for patient to complete
- SOAPP version I
  - Naturalistic observation / Concept mapping / Expert consensus
  - Face valid / intuitive
  - 24-items / Likert-like response scale (0 to 4)
  - Pilot study in 154 pts at Brigham & Women's showed reliability & predictive validity of scale
- SOAPP version II
  - Empirically-derived
  - Predictive validity (via prospective study)









Access an important tool that helps predict patient response to opioid medications.

#### DOWNLOAD THE SOAPP

Download a free copy of the SOAPP tool and SOAPP Monitoring Recommendations.

Click for more



#### CONTACT THE SOAPP TEAM

E-mail us any questions about the tool or to share your impressions of the SOAPP tool.

Click for more N

#### ABOUT THE SOAPP

The Screener and Opioid Assessment for Patients in Pain (SOAPP) is a tool to facilitate treatment planning for chronic pain patients being considered for long-term opioid treatment.

#### SOAPP version 1.0 is:

- A 24 item paper and pencil questionnaire
- ✓ Takes < 10 minutes to complete and simple to score</p>
- Developed based on expert consensus
- Ideal for documenting decisions about the level of monitoring planned for a particular patient or justifying referrals to specialty pain clinic.
- View [hyperlink to SOAPP development] preliminary reliability and validity data

Learn more about the SOAPP tool.



### **Utility in Clinical Practice**

- NEED to assure SOAPP can be readily integrated into clinical practice
- NEED to assure SOAPP is not used:
  - To deny pts access to pain medications
  - To supplant clinical judgement
- Background & instructions at www.painedu.org
- Diffusion/delivery system testing
  - Paper/pencil questionnaire
  - Electronic/PDA
  - IVR (interactive voice recognition)
  - Web-based
  - Fax back



## **COMM:** Current Opioid Misuse Measure

- Brief screener to help identify misuse in chronic pain pts who are already on opioid therapy
- Clinician checklist based upon input from 26 pain & addiction specialists
- Anticipated benefits:
  - Improved ongoing assessment of pts on chronic opioid therapy
  - Improved risk management & tx decision making
- Completed 2/04, but not yet validated



## Modified-Release Opioid RMP: Risk Assessment

- Safety surveillance
  - Trending
  - Signal detection
- Key elements
  - Postmarketing surveillance
  - ESRB-Endo Safety Review Board
  - Risk Management Team
  - Media screening



# Post Marketing Safety Surveillance Program (cont)

- On-going monitoring & evaluation of adverse events received from spontaneous reports
- Monitoring & evaluation of adverse events in on-going clinical trials for signals & trends



## Post Marketing Safety Surveillance Program: ESRB

- Multi-disciplinary Safety Review Board
  - Meets quarterly
  - Reviews post-marketing safety data collected on oxymorphone ER/IR
  - Investigates and reviews all cases of drug abuse/misuse, drug dependence and drug overdose to detect trends
  - Comparison of oxymorphone adverse event profile with other opioids via the FDA's Freedom of Information Act




# Post Marketing Safety Surveillance Program

- Risk Management Team
  - Internal multidisciplinary team
  - Expert advisors with safety, epidemiology, opioid, pain, and addiction medicine backgrounds
  - Monitoring nationally recognized databases such as DAWN
  - Media Surveillance
- Analysis of data
  - Stratification by events, geographic area, and age



# **Endo Safeguards to Prevent Opioid Diversion**





## Modified-Release Opioid RMP: Risk Communication

- Proactive risk communication
  - Education/ CME
  - "Dear Health Care Provider" letters
  - Patient brochures
  - Product labeling
  - Appropriate training of sales representatives
  - Partnering with professional societies



# Appropriate Training of Sales Representatives

- Messages on label with respect to:
  - Appropriate patient selection
  - Appropriate use of oxymorphone ER/IR
- Serve as an educational resource
  - Advocate responsible pain mgmt
  - Provide access to validated assessment and patient management tools
  - Provide balanced patient education materials



## Modified-Release Opioid RMP: Risk Intervention

- Risk Intervention
  - Intervention to targeted areas
    - Increase education on risk of abuse
    - Cooperate with local law enforcement agencies, FDA, and DEA
    - Maintain tight control of supply chain





# Assuring the Appropriate Use of Opioid Analgesics

# Appropriate Use of Opioid Analgesics

#### Rationale

- Studies have confirmed the usefulness of opioids in the treatment of chronic pain
- While controlled studies in chronic pain are needed, some studies in current literature suggest:
  - relatively low incidence of misuse among most pts who receive opioid analgesics for pain
  - potential for increased functioning & improved quality of life
- However....



# **Appropriate Use of Opioid Analgesics**

- Rationale (cont'd)
  - Physicians have legitimate concerns about prescribing opioids responsibly:
    - Concerns about addiction
    - Worry about possible abuse/misuse by patients (e.g., diversion and loss of control)
    - Liability and censure by regulatory agencies
    - Determining which pts are appropriate candidates for opioid therapy
    - Nat'l media attention re: abuse of prescription opioids has underscored these issues



### Assuring Pain Relief While Preventing Abuse: A Critical Balancing Act

- There is a need for scientifically-balanced education addressing:
  - Principles of prescribing opioid analgesics
    - "Pharmacology 101" to optimize efficacy, reduce AE's
  - Principles of risk assessment and management
- Endo recognizes that:
  - Access to opioid analgesics is critical to patients suffering from pain, but that
  - Risk of addiction & diversion must be addressed



PHARMACEUTICALS

# **Opioid Education Initiatives for Physicians**

- National Initiative on Pain Control
- McGraw Hill & NIH handbooks
- Primary Care & Resident "Essentials of Pain Mgmt" courses
- AAFP, STFM, ACP, and HHS Educational Initiatives
- "Appropriate Use of Opioids" kit
  - Physician, patient & family education materials
  - Pain assessment tools
  - Prototype pain mgmt agreements & documentation templates
- Scientific Resource Center at national congresses



## **Opioid Education Initiatives for Pharmacists**

- Critical link between physician & patient
  - Can enhance compliance, reduce risk of AE's, alert physician to any red flags
- US Pharmacist & PharmAlert publications
- APhA new product bulletins
- ASHP pain traineeship
- Symposia at annual meetings



## Opioid Education Initiatives for Patients & Families

- Critical that patients/families understand both risks & benefits of opioid analgesics
- "Understanding Your Pain: Taking Oral Opioid Analgesics" booklet
- "Using a Pain Assessment Scale" brochure
- Brief Pain Inventory tear-pads
- National patient initiatives
  - APF, NPF, AACPI, ACPA
  - Dept of Health & Human Services



### Partnering with Professional Societies

#### AAFP

- CE-accredited video & monograph
- Journal of Family Practice supplement
- support of state academy initiatives

#### STFM

- Workshops, roundtables & handbooks at annual meetings
- Precourses at regional meetings; regional "train the trainer"

#### ACP

- core curriculum & handbooks at annual meetings
- pocket reference guides

#### PriMed

Symposia at regional PriMed meetings



### Your Recommendations

- > Other opportunities?
- > Unmet needs?
- What can actually help effect meaningful change?

